IMPACC convalescent data collection, including Patient Reported Outcomes (PROs) and home visit sampling

2019冠状病毒病队列免疫表型评估（IMPACC）：临床和数据协调 中心（CDCC） 项目摘要 2019年12月，中国武汉的一系列呼吸道疾病定义了全球大流行的爆发 涉及新型冠状病毒（SARS-CoV-2）和相关呼吸道疾病（COVID-19）。存在重大 正在进行的研究工作，以了解SARS-CoV-2感染和相关的COVID-19疾病。的 免疫表型评估Covid-19队列（IMPACC）监测研究是基于一项观察性 将收集详细的临床、实验室和影像学数据并与生物采样协调的队列 血液和呼吸道分泌物以及鼻分泌物中的病毒脱落。监测研究的目的是 识别COVID-19相关易感性和/或进展的免疫表型和基因组特征。 IMPACC临床和数据协调中心（CDCC）将提供临床和数据协调支持 在IMPAC研究中。这包括全面的研究协调和项目管理支持， 所有参与IMPACC的临床和核心实验室研究中心，包括初始研究中心培训和持续研究支持 完成研究入组和随访。CDCC将为临床研究中心提供实时 样本跟踪和数据采集能力，包括样本采集所需的所有耗材和试剂 收集、用于数据录入的电子病例报告表（eCRF）和质量控制/质量保证（QC/QA） 确保高质量的样本收集和数据采集。最后，CDCC将设计数字化 基础设施组件，以促进研究终点的数据管理、数据存储和数据分析， 安全性数据，包括主要终点的中期和最终分析，持续的安全性和结局监测， 以及对次要/探索性终点的生物信息学分析支持。

IMmunoPhenotyping Assessment in a COVID-19 Cohort (IMPACC): Clinical and Data Coordinating Center (CDCC) Project summary In December 2019, a cluster of respiratory illness in Wuhan, China defined the onset of a global pandemic involving a novel coronavirus (SARS-CoV-2) with associated respiratory disease (COVID-19). There are major research efforts underway to understand SARS-CoV-2 infections and the associated COVID-19 disease. The IMmunoPhenotyping Assessment Covid-19 Cohort (IMPACC) surveillance study is based upon an observational cohort that will collect detailed clinical, laboratory, and radiographic data in coordination with biologic sampling of blood and respiratory secretions and viral shedding in nasal secretions. The goal of the surveillance study is to identify immunophenotypic and genomic features of COVID-19-related susceptibility and/or progression. The IMPACC Clinical and Data Coordinating Center (CDCC) will provide clinical and data coordination support for the IMPACC study. This includes comprehensive study coordination and project management support across all participating IMPACC clinical and Core laboratory sites, including initial site training and ongoing study support through the completion of study enrollment and follow-up. The CDCC will provide clinical sites with real-time sample tracking and data capture capabilities, including all necessary supplies and reagents for sample collection, electronic case report forms (eCRFs) for data entry, and quality control/quality assurance (QC/QA) processes to ensure high quality sample collection and data capture. Finally, the CDCC will design digital infrastructure components to facilitate data management, data storage, and data analysis of study endpoint and safety data, including interim and final analysis of primary endpoints, ongoing safety and outcome monitoring, and bioinformatics analytic support for secondary/exploratory endpoints.